image
Healthcare - Biotechnology - NASDAQ - DE
$ 104.1
3.09 %
$ 25 B
Market Cap
-32.53
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BNTX stock under the worst case scenario is HIDDEN Compared to the current market price of 104 USD, BioNTech SE is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BNTX stock under the base case scenario is HIDDEN Compared to the current market price of 104 USD, BioNTech SE is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BNTX stock under the best case scenario is HIDDEN Compared to the current market price of 104 USD, BioNTech SE is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BNTX

image
$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.75 B REVENUE
-27.96%
-1.31 B OPERATING INCOME
-190.37%
-678 M NET INCOME
-57.14%
208 M OPERATING CASH FLOW
-96.13%
-2.08 B INVESTING CASH FLOW
70.07%
-45.9 M FINANCING CASH FLOW
94.10%
1.19 B REVENUE
-3.11%
149 M OPERATING INCOME
1315.24%
301 M NET INCOME
54.10%
-463 M OPERATING CASH FLOW
25.01%
607 M INVESTING CASH FLOW
526.95%
-7.3 M FINANCING CASH FLOW
7.59%
Balance Sheet BioNTech SE
image
Current Assets 18.8 B
Cash & Short-Term Investments 16.8 B
Receivables 1.52 B
Other Current Assets 496 M
Non-Current Assets 3.73 B
Long-Term Investments 1.25 B
PP&E 1.18 B
Other Non-Current Assets 1.29 B
74.50 %6.76 %5.57 %5.25 %5.72 %Total Assets$22.5b
Current Liabilities 2.52 B
Accounts Payable 427 M
Short-Term Debt 39.5 M
Other Current Liabilities 2.06 B
Non-Current Liabilities 595 M
Long-Term Debt 215 M
Other Non-Current Liabilities 381 M
13.68 %65.96 %6.88 %12.21 %Total Liabilities$3.1b
EFFICIENCY
Earnings Waterfall BioNTech SE
image
Revenue 2.75 B
Cost Of Revenue 541 M
Gross Profit 2.21 B
Operating Expenses 3.52 B
Operating Income -1.31 B
Other Expenses -637 M
Net Income -678 M
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)(1b)(1b)(1b)(1b)3b(541m)2b(4b)(1b)637m(678m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.32% GROSS MARGIN
80.32%
-47.77% OPERATING MARGIN
-47.77%
-24.18% NET MARGIN
-24.18%
-3.43% ROE
-3.43%
-2.95% ROA
-2.95%
-6.44% ROIC
-6.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioNTech SE
image
14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)2018201820192019202020202021202120222022202320232024202420252025
Net Income -678 M
Depreciation & Amortization 298 M
Capital Expenditures -452 M
Stock-Based Compensation 101 M
Change in Working Capital 1.22 B
Others -734 M
Free Cash Flow -245 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioNTech SE
image
Wall Street analysts predict an average 1-year price target for BNTX of $121 , with forecasts ranging from a low of $93 to a high of $150 .
BNTX Lowest Price Target Wall Street Target
93 USD -10.66%
BNTX Average Price Target Wall Street Target
121 USD 16.49%
BNTX Highest Price Target Wall Street Target
150 USD 44.09%
Price
Max Price Target
Min Price Target
Average Price Target
150150140140130130120120110110100100909080807070Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
2.11 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.5002.5002.0002.0001.5001.5001.0001.0000.5000.5000.0000.0002.1112.1120222022
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership BioNTech SE
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. globenewswire.com - 1 week ago
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. zacks.com - 2 weeks ago
Vaccine stocks fall following FDA resignation Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more. youtube.com - 1 month ago
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization. fastcompany.com - 1 month ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies. nypost.com - 1 month ago
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F. cnbc.com - 1 month ago
Biotech stocks tumble on reports FDA's top vaccine regulator to leave Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments. reuters.com - 1 month ago
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Metastatic Melanoma. Refractory Metastatic Melanoma Emerging Drugs Chapters This segment of the Refractory Metastatic Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Refractory Metastatic Melanoma Emerging Drugs globenewswire.com - 1 month ago
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ruling, remain pending, which poses short-term headwinds. Nevertheless, BNTX's robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology. seekingalpha.com - 1 month ago
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Flynn - Morgan Stanley Harry Gillis - Berenberg Cory Kasimov - Evercore Sadia Rahman - Wells Fargo Asthika Goonewardene - Truist Securities Yaron Werber - TD Cowen Jessica Fye - JP Morgan Operator Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. seekingalpha.com - 1 month ago
BioNTech Stock Drops as Sales Outlook Disappoints U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results. investopedia.com - 1 month ago
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations BioNTech SE  BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents. benzinga.com - 1 month ago
8. Profile Summary

BioNTech SE BNTX

image
COUNTRY DE
INDUSTRY Biotechnology
MARKET CAP $ 25 B
Dividend Yield 0.00%
Description BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Contact An der Goldgrube 12, Mainz, 55131 https://www.biontech.de
IPO Date Oct. 10, 2019
Employees 6772
Officers Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer & Member of Management Board Mr. Jens H. Holstein Chief Financial Officer & Member of Management Board Ms. Beate Berns Senior Vice President of Global Human Resources Dr. Ugur Sahin M.D. Co-Founder, Chief Executive Officer & Chair of the Management Board Dr. Sierk Poetting Ph.D. MD, Chief Operating Officer & Member of Management Board Ms. Lisa Birringer Senior Vice President of Global Financial Reporting & Accounting Dr. James Timothy Patrick Ryan Ph.D. Chief Legal & Business Officer & Member of the Management Board Mr. Zach Taylor Senior Vice President of Corporate Development & Strategy Mr. Ryan Richardson Chief Strategy Officer, MD & Member of Management Board Ms. Annemarie Hanekamp Chief Commercial Officer & Member of Management Board